[fusion_builder_container hundred_percent=”yes” overflow=”visible”][fusion_builder_row][fusion_builder_column type=”1_1″ background_position=”left top” background_color=”” border_size=”” border_color=”” border_style=”solid” spacing=”yes” background_image=”” background_repeat=”no-repeat” padding=”” margin_top=”0px” margin_bottom=”0px” class=”” id=”” animation_type=”” animation_speed=”0.3″ animation_direction=”left” hide_on_mobile=”no” center_content=”no” min_height=”none”]
Low AMH does not predict live births.
Last month, Fertility and Sterility published a study involving live births from IVF and the measurement of AMH.
What’s great about this study? It’s has a large study population (69,336 women undergoing fresh and frozen embryo transfers). The study clearly found AMH has no impact on lowering live births.
My experience has been that fertility clinics feel AMH can only lead to poor results in IUI/IVF. My observation with women who have been diagnosed with low AMH, they can get pregnant.
The most important concept to remember during IVF – quality over quantity when it comes to egg making. Yes, low AMH will probably decrease the amount of egg you produce, but it doesn’t necessarily decrease the quality of your eggs. It only takes one good quality egg (with good quality sperm) to make a embryo.
Now, women with low AMH can read this study and know they can get pregnant and have a healthy baby.
If you have low AMH, you can benefit from acupuncture. Acupuncture treatments can increase your pelvic blood flow (reproductive hormones are carried via the blood), release feel good hormones to help you relax and provide support through your fertility journey.
Antimüllerian hormone as a predictor of live birth following assisted reproduction: an analysis of 85,062 fresh and thawed cycles from the Society for Assisted Reproductive Technology Clinic Outcome Reporting System database for 2012–2013
Presented, in part, as an oral presentation at the 73rd Annual Meeting of the American Society for Reproductive Medicine, San Antonio, Texas, October 28- November 1, 2017.
Reshef Tal, M.D., Ph.D., David B. Seifer, M.D., Ethan Wantman, M.B.A., Valerie Baker, M.D., Oded Tal, Ph.D.
Fertility and Sterility, February 2018
Retrospective analysis of Society for Assisted Reproductive Technology Clinic Outcome Reporting System database from 2012 to 2013.
Setting
Not applicable.
Patient(s)
A total of 69,336 (81.8%) fresh and 15,458 (18.2%) frozen embryo transfer (FET) cycles with AMH values.
Intervention(s)
None.
Main Outcome Measure(s)
Live birth.
Result(s)
A total of 85,062 out of 259,499 (32.7%) fresh and frozen-thawed autologous non–preimplantation genetic diagnosis cycles had AMH reported for cycles over this 2-year period. Of those, 70,565 cycles which had embryo transfers were included in the analysis. Serum AMH was significantly associated with live birth outcome per transfer in both fresh and FET cycles. Multiple logistic regression demonstrated that AMH is an independent predictor of live birth in fresh transfer cycles and FET cycles when controlling for age, body mass index, race, day of transfer, and number of embryos transferred. Receiver operating characteristic (ROC) curves demonstrated that the areas under the curve (AUC) for AMH as predictors of live birth in fresh cycles and thawed cycles were 0.631 and 0.540, respectively, suggesting that AMH alone is a weak independent predictor of live birth after ART. Similar ROC curves were obtained also when elective single-embryo transfer (eSET) cycles were analyzed separately in either fresh (AUC 0.655) or FET (AUC 0.533) cycles, although AMH was not found to be an independent predictor in eSET cycles.
Conclusion(s)
AMH is a poor independent predictor of live birth outcome in either fresh or frozen embryo transfer for both eSET and non-SET transfers.[/fusion_builder_column][/fusion_builder_row][/fusion_builder_container]